Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study - 05/03/16
, Axel Finckh a, Lara Fischer b, Camillo Ribi b, Danielle Gascon a, Jörg D. Seebach b, Pierre-André Guerne aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
Rituximab (RTX) is increasingly used in patients with refractory rheumatoid arthritis (RA) and other severe autoimmune diseases (AID). In practice, many clinicians are reluctant to prescribe RTX in patients with low B-cell counts because of the presumed risk of infection. The aim of this study was therefore to investigate whether B-cell counts before treatment or retreatment with RTX predict the occurrence of infections.
Methods |
Observational, single-centre study of 161 patients treated with RTX for RA and other AID at a tertiary hospital. CD19+ B-cell counts were assessed by flow cytometry and multivariate statistical analysis adjusted for various potential predictors was performed.
Results |
The rate of severe infection was 5.9/100 patient-years in RA patients and 24.9 in non-RA AID (P<0.001). Low B-cell counts at the time of RTX infusion were not associated with subsequent severe (HR=0.55, P=0.60) or overall infection (HR=0.85, P=0.58). Significant pre-treatment predictors of severe infection were a diagnosis other than RA (HR=4.68, P<0.001), immunoglobulin (Ig) G levels <7g/L (HR=2.36, P=0.01), age (HR=1.03, P=0.01), and diabetes (HR=3.61, P=0.01).
Conclusions |
Low B-cell counts before RTX infusion did not predict subsequent infections in this population treated with RTX for RA and other AID, therefore not supporting the practice of pre-treatment assessment of B-cells. Nevertheless, a higher risk of severe infection was confirmed for low pre-treatment IgG levels, older age, diabetes, and AID other than RA.
Le texte complet de cet article est disponible en PDF.Keywords : Rituximab, Rheumatoid arthritis, Autoimmune disease, Infection, B-cells
Plan
Vol 83 - N° 2
P. 191-197 - mars 2016 Retour au numéro
Article précédent
- Evaluation of physiotherapy in a prospective cohort of early axial spondyloarthritis. Data from the DESIR cohort
- Cécile Escalas, Marie Dalichampt, Maxime Dougados, Serge Poiraudeau
- Randomised study versus control group of customised therapeutic education for patients in follow-up for rheumatoid arthritis
- Marianne Pot-Vaucel, Marie-Pierre Aubert, Pascale Guillot, Joëlle Glémarec, Jean-Marie Berthelot, Benoit Le Goff, Yves Maugars
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?